Skip to main content

Metacrine, Inc. (MTCR)

NASDAQ: MTCR · IEX Real-Time Price · USD
3.15
+0.15 (5.00%)
After-hours:Sep 17, 2021 4:15 PM EDT
3.00
-0.10 (-3.23%)
At close: Sep 17, 4:00 PM
Market Cap79.58M
Revenue (ttm)2.18M
Net Income (ttm)-50.22M
Shares Out26.53M
EPS (ttm)-2.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume319,385
Open3.15
Previous Close3.10
Day's Range3.00 - 3.16
52-Week Range2.59 - 11.65
Betan/a
AnalystsStrong Buy
Price Target17.00 (+466.7%)
Est. Earnings DateNov 11, 2021

About MTCR

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic steatohepatitis (NASH); and is in Phase 2a clinical trial in combination with empagliflozin for the treatment of patients with type 2 diabetes mellitus and NASH. The company also develops MET642, which is in Phase 2a clinical trial for the treatment of ...

IndustryBiotechnology
IPO DateSep 16, 2020
Employees35
Stock ExchangeNASDAQ
Ticker SymbolMTCR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Metacrine stock is "Strong Buy." The 12-month stock price forecast is 17.00, which is an increase of 466.67% from the latest price.

Price Target
$17.00
(466.67% upside)
Analyst Consensus: Strong Buy

News

Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...

1 week ago - GlobeNewsWire

Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...

1 week ago - GlobeNewsWire

Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...

1 week ago - GlobeNewsWire

Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...

1 month ago - GlobeNewsWire

Metacrine to Present at 2021 Canaccord Genuity Growth Conference

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...

1 month ago - GlobeNewsWire

Metacrine to Present New Preclinical Data in Inflammatory Bowel Disease (IBD) at European Crohn's and Colitis Organis...

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...

2 months ago - GlobeNewsWire

Metacrine and Its Partners to Present Data at the EASL International Liver Congress™ 2021

SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...

3 months ago - GlobeNewsWire

Metacrine Achieves Full Enrollment for MET409 Phase 2a Combination Trial in Patients With Type 2 Diabetes and NASH

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal di...

3 months ago - GlobeNewsWire

Metacrine to Present at 2021 Jefferies Healthcare Conference

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...

3 months ago - GlobeNewsWire

Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virt...

Preclinical data demonstrate synergistic effects between FXR agonist and JAK inhibitor, suggesting the potential for a change in the treatment paradigm for IBD Preclinical data demonstrate synergistic e...

4 months ago - GlobeNewsWire

Metacrine Achieves Enrollment Target for MET642 Phase 2a Trial Interim Analysis

SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...

4 months ago - GlobeNewsWire

Metacrine to Present at 2021 RBC Global Healthcare Conference

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal dis...

4 months ago - GlobeNewsWire

Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal d...

5 months ago - GlobeNewsWire

Metacrine Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Interim Data from the Phase 2a Trial of MET642 in NASH Patients On-Track to be Reported in the Fourth Quarter of 2021

6 months ago - GlobeNewsWire

Metacrine to Present Final Results from Phase 1 Trial of MET642, an Optimized FXR Agonist, at the 2021 NASH-TAG Confe...

Sustained pharmacodynamic effects with once-daily oral dosing, without increases in LDL cholesterol or pruritus at any dose level in healthy volunteers Sustained pharmacodynamic effects with once-daily ...

6 months ago - GlobeNewsWire

Metacrine Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...

6 months ago - GlobeNewsWire

Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH

On-track for Interim Analysis Readout in the Fourth Quarter of 2021 On-track for Interim Analysis Readout in the Fourth Quarter of 2021

6 months ago - GlobeNewsWire

Metacrine to Present at H.C. Wainwright 2021 Global Life Sciences Conference

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with ...

6 months ago - GlobeNewsWire

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...

7 months ago - GlobeNewsWire

3 Net-Net Working Capital Stocks

There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has reassessed t...

Other symbols:ABIOATHA
7 months ago - GuruFocus

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evidence that t...

7 months ago - GlobeNewsWire

Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...

8 months ago - GlobeNewsWire

Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-Based Combi...

8 months ago - GlobeNewsWire

Metacrine Reports Positive Results from Phase 1 Trial of MET642

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase

9 months ago - GlobeNewsWire

Metacrine to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with l...

9 months ago - GlobeNewsWire